M&A · Healthcare · Buyer's industry: Pharmaceutical Preparations
Immunome Inc. to acquire Morphimmune
Announced Jun 29, 2023 · Closed Oct 4, 2023 · Private target
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock$5.91 per share
Transaction
- Acquirer
- Immunome Inc. (IMNM)
- Target
- Morphimmune
- Buyer type
- Strategic
- Offer price per share
- $5.91
- Enterprise value
- —
- Status
- Closed Oct 4, 2023
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Stifel
- To the target
- TD Cowen
Classification
- Sector
- Healthcare
- Buyer's industry
- Pharmaceutical Preparations